XTX Topco Ltd Buys Shares of 21,413 Bausch Health Cos Inc. (NYSE:BHC)

XTX Topco Ltd bought a new stake in Bausch Health Cos Inc. (NYSE:BHC) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 21,413 shares of the company’s stock, valued at approximately $139,000.

Several other institutional investors also recently bought and sold shares of BHC. JPMorgan Chase & Co. grew its position in Bausch Health Cos by 1,246.0% in the 4th quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company’s stock valued at $160,000 after acquiring an additional 18,366 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Bausch Health Cos by 12.5% in the 4th quarter. Geode Capital Management LLC now owns 715,570 shares of the company’s stock valued at $5,767,000 after buying an additional 79,488 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Bausch Health Cos by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company’s stock valued at $209,000 after buying an additional 1,896 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Bausch Health Cos by 1,761.5% in the 4th quarter. Renaissance Technologies LLC now owns 495,172 shares of the company’s stock valued at $3,991,000 after buying an additional 468,572 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Bausch Health Cos in the 4th quarter valued at about $180,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BHC has been the subject of several recent research reports. Royal Bank Of Canada lifted their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd.

Bausch Health Cos Price Performance

BHC stock opened at $7.52 on Friday. The business has a 50 day moving average price of $6.30 and a 200 day moving average price of $6.02. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 28.90 and a beta of 0.41. Bausch Health Cos Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $9.85. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The firm had revenue of $2.57 billion during the quarter, compared to analysts’ expectations of $2.47 billion. Equities research analysts anticipate that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Insider Activity

In related news, Director John Paulson bought 34,721,118 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were acquired at an average price of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the acquisition, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. This trade represents a 96.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 44,316,834 shares of company stock valued at $369,628,560 over the last quarter. Insiders own 8.05% of the company’s stock.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.